자유게시판

• 목록
• 답변
• 글쓰기
• 게시판 리스트 옵션
  • 수정
  • 삭제

Introduction Summary: This observational study evaluated the efficacy and tolerability of tretinoin gel 0.025% in a real-world setting among patients with acne vulgaris. Information was collected in hindsight from patient dossiers at a skin clinic during a 12-month interval. The key outcome metrics consisted of shifts in acne lesion tallies (inflammatory and non-inflammatory) and patient-documented acceptability. Findings showed a notable decrease in both inflammatory and non-inflammatory lesions following 12 weeks of therapy. While initial irritation was common, it generally resolved within the first few weeks. This investigation endorses the sustained utilization of tretinoin gel 0.025% as an efficient and typically well-endured treatment for acne vulgaris in everyday medical settings.

Opening: Acne vulgaris constitutes a widespread persistent inflammatory skin ailment influencing a substantial part of the global populace, chiefly adolescents and young adults. Treatment alternatives vary greatly, extending from topical retinoids to oral antibiotics and systemic approaches. Tretinoin, being a topical retinoid, is a commonly utilized and solidly proven treatment for acne because of its skill in decreasing sebum generation, stimulating epidermal cell regeneration, and reducing inflammation. Even though various clinical tests have proven the potency of tretinoin, real-life observational investigations are vital to gauge its efficiency and endurance in diverse patient cohorts and under everyday clinical conditions. This study planned to in hindsight assess the therapeutic outcomes and endurance of tretinoin gel 0.025% in people with acne vulgaris treated at a dermatology facility.

Procedures: This retrospective monitoring study involved adult patients (aged 18 and older) diagnosed with acne vulgaris prescribed tretinoin gel 0.025% as the primary care approach between January 1, 2022, and December 31, 2022, at a single skin clinic. Patient dossiers were reviewed to collect details on demographics (age, gender), acne seriousness at outset (assessed with a modified Global Acne Grading System [mGAGS]), care duration, changes in lesion tallies (inflammatory and non-inflammatory) at baseline, 4 weeks, 8 weeks, and 12 weeks, and patient-reported endurance (assessed through practitioner notes documenting patient concerns). Data on concomitant medications were also recorded.

The mGAGS score was calculated by summing the scores for inflammatory lesions (papules, pustules, nodules, cysts) and non-inflammatory lesions (comedones). Every lesion form was designated a value based on its severity and number. Acceptability was gauged based on clinician notes of patient-documented side effects, including dryness, irritation, erythema, and peeling. The harshness of these adverse reactions was categorized as mild, moderate, or severe.

Statistical analysis was undertaken utilizing descriptive statistics to condense the demographic and clinical characteristics of the study participants. Paired t-tests were utilized to match lesion counts at outset and at all follow-up times. Variations in lesion counts were furthermore analyzed via repeated measures ANOVA. The link between initial acne intensity and therapy reaction was evaluated with correlation analysis.

Data: A total of 100 individuals (62 females, 38 males) with a mean age of 24.5 ± 5.2 years were incorporated in the investigation. The typical baseline mGAGS value was 18.7 ± 6.3. At baseline, the mean number of inflammatory lesions was 9.2 ± 4.1 and the mean number of non-inflammatory lesions was 9.5 ± 3.8.

Significant lessenings in both inflammatory and non-inflammatory lesion counts were observed at all follow-up times compared to starting (p<0.001 for all matches). The average diminishment in inflammatory lesions at 12 weeks was 7.1 ± 2.9, and the average diminishment in non-inflammatory lesions was 6.8 ± 2.7. Repeated measures ANOVA showed a significant time effect on both inflammatory and non-inflammatory lesion counts (p<0.001 for both).

Starting irritation was noted by 72% of patients, with most having mild irritation (60%). Moderate irritation was reported by 12% of patients, and severe irritation was reported by only 10% of patients. The majority of patients whose irritation was mild to moderate reported resolution of symptoms within 4 weeks of initiating treatment. No patients discontinued treatment due to intolerability.

Examination: This study presents real-life evidence promoting the efficiency and endurance of tretinoin gel 0.025% in treating acne vulgaris. The significant reduction in both inflammatory and non-inflammatory lesion counts observed in this study is consistent with findings from previous clinical trials. The large incidence of beginning irritation is also in accordance with the acknowledged side effect features of tretinoin. However, the fact that the majority of patients experienced only mild irritation and that the irritation generally resolved within a few weeks suggests that tretinoin gel 0.025% is generally well-tolerated.

The retroactive nature of this analysis is a shortcoming, as it is exposed to potential biases related to data assembly and omitted data. Additionally, the investigation was performed at a single facility, which might constrain the generalizability of the findings to different populations. Upcoming forward-looking studies with bigger sample groups and several centers are required to additionally verify these results.

Final Thoughts: This observational study supports the use of tretinoin gel 0.025% as an effective and generally well-tolerated treatment for acne vulgaris in a real-world clinical setting. Although starting irritation is frequent, it is typically mild and temporary. Doctors ought to inform patients regarding the possibility of early irritation and recommend methods to alleviate these adverse effects. Additional research is called for to probe the long-term impact and safety of tretinoin gel 0.025% in varied patient sets.